VERTEX PHARMACEUTICALS INC / MA Quarterly Costs and Expenses in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Total costs of sales and operating expenses for the period.
Summary
Vertex Pharmaceuticals Inc / Ma quarterly/annual Costs and Expenses history and growth rate from Q1 2010 to Q2 2024.
  • Vertex Pharmaceuticals Inc / Ma Costs and Expenses for the quarter ending June 30, 2024 was $6.16B, a 320% increase year-over-year.
  • Vertex Pharmaceuticals Inc / Ma Costs and Expenses for the twelve months ending June 30, 2024 was $10.7B, a 92.9% increase year-over-year.
  • Vertex Pharmaceuticals Inc / Ma annual Costs and Expenses for 2023 was $6.04B, a 30.6% increase from 2022.
  • Vertex Pharmaceuticals Inc / Ma annual Costs and Expenses for 2022 was $4.62B, a 3.53% decline from 2021.
  • Vertex Pharmaceuticals Inc / Ma annual Costs and Expenses for 2021 was $4.79B, a 43.1% increase from 2020.
Costs and Expenses, Trailing 12 Months (USD)
Costs and Expenses, Quarterly (USD)
Costs and Expenses, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $10.7B $6.16B +$4.69B +320% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-02
Q1 2024 $5.99B $1.55B -$44.7M -2.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $6.04B $1.53B +$260M +20.5% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-15
Q3 2023 $5.78B $1.45B +$238M +19.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-07
Q2 2023 $5.54B $1.47B +$377M +34.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-02
Q1 2023 $5.16B $1.6B +$539M +51% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $4.62B $1.27B +$74.3M +6.22% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-15
Q3 2022 $4.55B $1.21B +$278M +29.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-07
Q2 2022 $4.27B $1.09B -$741M -40.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $5.01B $1.06B +$220M +26.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-02
Q4 2021 $4.79B $1.19B +$313M +35.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-15
Q3 2021 $4.48B $930M +$63.6M +7.34% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-28
Q2 2021 $4.42B $1.83B +$1.02B +127% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 $3.39B $837M +$41.6M +5.24% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q4 2020 $3.35B $882M +$20.2M +2.35% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-11
Q3 2020 $3.33B $866M +$15.5M +1.83% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $3.31B $806M +$135M +20.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-30
Q1 2020 $3.18B $795M +$213M +36.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 $2.97B $862M +$119M +16.1% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-11
Q3 2019 $2.85B $850M +$272M +46.9% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-11
Q2 2019 $2.57B $671M +$92.1M +15.9% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-11
Q1 2019 $2.48B $582M +$69.7M +13.6% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-11
Q4 2018 $2.41B $742M +$216M +41.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $2.2B $579M -$325M -36% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $2.52B $579M +$87.9M +17.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 $2.43B $512M +$68M +15.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $2.37B $526M +$107M +25.5% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-13
Q3 2017 $2.26B $904M +$472M +109% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-13
Q2 2017 $1.79B $491M +$63.2M +14.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-13
Q1 2017 $1.72B $444M +$31.5M +7.63% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-13
Q4 2016 $1.69B $419M -$52.6M -11.1% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-15
Q3 2016 $1.74B $433M +$52.7M +13.9% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-15
Q2 2016 $1.69B $428M +$91M +27% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-15
Q1 2016 $1.6B $412M +$102M +32.8% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-15
Q4 2015 $1.5B $472M +$173M +58.2% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 $1.33B $380M +$58.7M +18.3% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 $1.27B $337M +$18.3M +5.73% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 $1.25B $310M -$24M -7.18% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 $1.27B $298M -$63.3M -17.5% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-16
Q3 2014 $1.34B $321M -$24.1M -6.97% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-16
Q2 2014 $1.36B $319M -$38.8M -10.9% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-16
Q1 2014 $1.4B $334M -$423M -55.8% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-16
Q4 2013 $1.82B $361M -$50M -12.2% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-13
Q3 2013 $1.87B $345M +$8.18M +2.43% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-13
Q2 2013 $1.86B $358M -$71.3M -16.6% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-13
Q1 2013 $1.94B $758M +$410M +118% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-13
Q4 2012 $1.52B $411M +$72M +21.2% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-11
Q3 2012 $1.45B $337M -$106M -24% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-11
Q2 2012 $1.56B $429M +$149M +53.1% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-11
Q1 2012 $1.41B $347M +$114M +48.6% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-11
Q4 2011 $1.3B $339M +$107M +46.2% Oct 1, 2011 Dec 31, 2011 10-K 2013-03-01
Q3 2011 $1.19B $443M +$220M +98.5% Jul 1, 2011 Sep 30, 2011 10-K 2013-03-01
Q2 2011 $969M $280M +$79.1M +39.3% Apr 1, 2011 Jun 30, 2011 10-K 2013-03-01
Q1 2011 $890M $234M +$50.9M +27.8% Jan 1, 2011 Mar 31, 2011 10-K 2013-03-01
Q4 2010 $839M $232M Oct 1, 2010 Dec 31, 2010 10-K 2012-02-22
Q3 2010 $223M Jul 1, 2010 Sep 30, 2010 10-K 2012-02-22
Q2 2010 $201M Apr 1, 2010 Jun 30, 2010 10-K 2012-02-22
Q1 2010 $183M Jan 1, 2010 Mar 31, 2010 10-K 2012-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.